Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

PURPOSE: Although durable responses can be achieved with tyrosine kinase inhibitors such as imatinib in melanomas harboring KIT mutations, the efficacy of alternative inhibitors after progression to imatinib and the activity of these agents on brain metastases is unknown. EXPERIMENTAL DESIGN: We con...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Carvajal, Richard D., Lawrence, Donald P., Weber, Jeffrey S., Gajewski, Thomas F., Gonzalez, Rene, Lutzky, Jose, O’Day, Steven J., Hamid, Omid, Wolchok, Jedd D., Chapman, Paul B., Sullivan, Ryan J., Teitcher, Jerrold B., Ramaiya, Nikhil, Giobbie-Hurder, Anita, Antonescu, Cristina R., Heinrich, Michael C., Bastian, Boris C., Corless, Christopher L., Fletcher, Jonathan A., Hodi, F. Stephen
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013827/
https://ncbi.nlm.nih.gov/pubmed/25695690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1630
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge